Xenon Pharmaceuticals
XENEXenon Pharmaceuticals is a clinical-stage neuroscience-focused biopharmaceutical company specializing in the discovery and development of therapeutics for neurological and psychiatric disorders.
Earnings
Next report
Aug 10, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Xenon Pharmaceuticals is a clinical-stage neuroscience-focused biopharmaceutical company specializing in the discovery and development of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in ion channel biology to advance a pipeline of potassium and sodium channel modulators targeting epilepsy, depression, and pain. Its core value proposition is centered on developing differentiated small-molecule candidates that address significant unmet needs in CNS disorders through novel mechanisms of action.
A leading developer of Kv7 potassium channel openers with a late-stage clinical candidate, azetukalner, positioned for multiple CNS indications.
Questions, answered.
- What is Xenon Pharmaceuticals's market cap?
- Xenon Pharmaceuticals (XENE) has a market capitalization of $6.4B and trades on NASDAQ.
- Who are Xenon Pharmaceuticals's competitors?
- Xenon Pharmaceuticals's key competitors include Neumora Therapeutics, Inc., Biohaven Ltd., Axsome Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Xenon Pharmaceuticals partner with?
- Xenon Pharmaceuticals's notable partners include Neurocrine Biosciences, Inc., 1st Order Pharmaceuticals, Inc., Bausch Health Companies Inc..
- What subsidiaries does Xenon Pharmaceuticals have?
- Xenon Pharmaceuticals's subsidiaries include Xenon Pharmaceuticals USA Inc..
- Where is Xenon Pharmaceuticals headquartered?
- Xenon Pharmaceuticals is headquartered in Canada and employs approximately 259 people. It has been publicly traded since 2014.